The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients
Parlak A et al. – In this study Long pentraxin 3 (PTX3) and Asymmetric dimethylarginine (ADMA) levels investigated of valsartan and nebivolol’s effect on newly diagnosed hypertensive patients.
- Long pentraxin 3 (PTX3) is a recently discovered multimeric inflammatory mediator that is structurally linked to short pentraxins, such as C–reactive protein (CRP) and serum amyloid P component.
- PTX3 is produced by a variety of tissues and cells, including vascular endothelial cells and macrophages.
- Because of its extrahepatic synthesis (in contrast to CRP), the PTX3 level is believed to be a true independent indicator of disease activity because PTX3 is produced at sites of inflammation and is intimately linked to endothelial dysfunction.
- PTX3 also has key functions in innate immunity and has been identified in atherosclerotic lesions.
- Previously, PTX3 was associated with myocyte damage in myocardial infarction (MI), mortality after MI, and unstable angina.
- Because PTX3 release is likely a specific response to vascular damage, PTX3 levels may provide more explicit information on development and progression of atherosclerosis than nonspecific markers like CRP and interleukin–6.
- Asymmetric dimethylarginine (ADMA) is a naturally occurring component of human blood plasma.
- More than one decade ago ADMA was first reported to exert biological effects by inhibiting nitric oxide synthesis.
- Many researchers today agree that ADMA may play a prominent role in the pathogenesis and in the progression of cardiovascular diseases.